Drugs / gp120W61D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00027365 | ? → Jun 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp120W61D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00027365 ↗ |
| Modality | Vaccine | “the investigational vaccines NefTat and gp120w61d are safe and tolerable in humans” NCT00027365 ↗ |
| Route | Intramuscular | “Vaccinations are administered intramuscularly at 3 time points (entry, 1 month, and 3 months).” NCT00027365 ↗ |